Drug Profile
Research programme: fixed-dose combination therapeutics - Daewoong Pharmaceutical
Alternative Names: DWJ 1325; DWJ 1330; DWJ 1340Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperlipidaemics; Antitussives; Antiulcers
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cough; Hyperlipidaemia; Peptic ulcer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Peptic-ulcer in South Korea (PO)
- 28 Feb 2019 No recent reports of development identified for research development in Cough in South Korea (PO)
- 28 Feb 2019 No recent reports of development identified for research development in Hyperlipidaemia in South Korea (PO)